Table 1.
Baseline characteristics of Phase 2a patients.
| Active | Control | All patients | |
|---|---|---|---|
| N = 21 | N = 11 | N = 32 | |
| Age (years), median (Q1, Q3) | 80 (73, 81) | 79 (77, 83) | 80 (74, 83) |
| Baseline BCVA (ETDRS letters), median (Q1, Q3) | 63 (50, 71) | 63 (53, 69) | 63 (50, 70) |
| Baseline center point thickness (μm), median (Q1, Q3) | 328 (285, 388) | 349 (307, 515) | 333 (296,460) |
| Number treatment naïve | 1 (5%) | 2 (18%) | 3 (9%) |
| Previous anti-VEGF injections, median (Q1, Q3) | 10 (5,13) | 8 (3,24) | 9 (5,14) |
| Fibrosis at baseline | 17 (81%) | 10 (91%) | 27 (84%) |
| PED at baseline | 7 (33%) | 4 (36%) | 11 (34%) |